Apixaban levels in Asian patients with atrial fibrillation
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at how the body processes the blood thinner apixaban in Asian patients with atrial fibrillation (an irregular heartbeat). The goal is to better understand dosing to improve safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with atrial fibrillation (an irregular heartbeat).
- You have been taking apixaban (also known as Eliquis) at a dose of either 2.5 mg or 5 mg twice daily for at least 3 days in a row.
- You do not have severe kidney disease that requires dialysis.
- You have not had a sudden kidney injury in the past 3 months.
- You do not have severe liver disease (Child-Pugh class C cirrhosis).
- You are not taking certain medications that can interfere with apixaban, such as ketoconazole, rifampicin, or St. John's Wort (some heart medications like amiodarone, verapamil, or diltiazem are allowed).
- You do not have a bowel condition that severely affects how your body absorbs medications, like short bowel syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well patients with atrial fibrillation take their apixaban medication and whether it is safe. It aims to see if using apixaban for the first time works well without causing bleeding problems.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study tests whether a mobile app can help people with atrial fibrillation learn more about their blood thinner, apixaban (Elxaban), and use it correctly. Participants use the app to get education and track their medication.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
This study checks how apixaban (a blood thinner) moves through the body in people who are on peritoneal dialysis and have non-valvular atrial fibrillation. It may help confirm the safest and most effective dosing for patients who have little or no remaining kidney function.
This trial tests whether apixaban, a blood thinner, works well for people with atrial fibrillation who also have heart or circulation conditions. It uses a smartphone app to help track your treatment.
Hear when a new Non Valvular Atrial Fibrillation (nv AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.